Dr Neal Rosen
Dr. Neal Rosen is the Director of the Center for Mechanism-Based Therapeutics at Memorial Sloan-Kettering Cancer Center, where he is also a Member in the Program in Molecular Pharmacology and Chemistry and the incumbent of the Enid A. Haupt Chair in Medical Oncology.
His major interests include the identification and study of the key molecular events responsible for the dysregulation of growth signaling in carcinomas and the use of this information for the development of effective therapeutic strategies. He has played an important role in the development of multiple inhibitors of receptor mediated signal transduction and has established and validated the concept the Hsp90 protein chaperone is a therapeutic target.
Recently, he has generated the concept that oncoprotein induced feedback inhibition of the signaling network is a major determinant of the transformed phenotype and the response of the tumor to targeted therapy. Currently his laboratory work focuses on using pharmacologic and genetic approaches to develop a detailed understanding of feedback and cross-talk among oncogeneactivated pathways in order to develop rational strategies for combination therapy. Recent work from the Rosen laboratory on ERK, mutant BRAF and PI3K/AKT signaling, the implications of the kinetics of pathway inhibition, and the consequences of relief of negative feedback by oncoprotein inhibitors has led to multiple clinical trials at Memorial Sloan-Kettering and other cancer centers in the United States and internationally.
Dr. Rosen received his undergraduate degree in Chemistry from Columbia College and an MD, PhD in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women’s Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer Institute. He was on the senior staff of the Medicine Branch at the NCI prior to joining the faculty of Memorial SloanKettering Cancer Center.